Search clinical trials for: glycopyrronium (NVA237)

Total 115 results

Novartis Pharmaceuticals

Recruiting

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma

Asthma

Spain, Hungary, United Kingdom, South Africa, Colombia, Guatemala, Bulgaria, Poland
Novartis

Completed

Safety and Tolerability of 28 Days Treatment With Glycopyrronium Bromide (NVA237) (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease (COPD)

United States, Spain, Turkey, France, Netherlands, Germany
Novartis Pharmaceuticals

Completed

Efficacy, Safety and Tolerability of the Co-administration of NVA237 Plus Indacaterol Once Daily Versus Indacaterol Once Daily in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (GLOW6)

Chronic Obstructive Pulmonary Disease (COPD)

Greece, Belgium, Bulgaria, Turkey, Hungary, Slovakia, Spain, United Kingdom, Russian Federation, Ireland
Novartis Pharmaceuticals

Completed

Efficacy and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States, Germany, Hungary, Belgium, Poland, Spain, Netherlands
Novartis Pharmaceuticals

Completed

Bronchodilator Effects and Safety of Glycopyrronium Bromide (25 ug and 50 ug o.d.) in Asthma

Asthma

Germany, United States, Belgium, Latvia, Lithuania, Japan
Novartis Pharmaceuticals

Completed

A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (SHINE)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Russian Federation, Taiwan, Canada, Germany, Philippines, South Africa, Spain, United Kingdom, Turkey, Hungary, Guatemala, Australia, Bulgaria, France, Poland, Switzerland, Slovakia, Japan
Novartis

Completed

1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD) (GLOW2)

Chronic Obstructive Pulmonary Disease

United States, Argentina, Germany, Russian Federation, France, Israel, Korea, Republic of, Italy, Poland, Chile, Mexico, Peru, Canada, Hungary, Netherlands, New Zealand
Convalife (Shanghai) Co., Ltd.

Not yet recruiting

CVL237 Tablets for APDS/PASLI

PI3K and P110delta Hyperactivation Syndrome

China
Novartis Pharmaceuticals

Completed

Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD Regimen

COPD

Germany, Belgium, Poland, Romania, Italy, Spain, Estonia, Russian Federation, Austria, France, Slovakia, Czechia, Latvia, Lithuania, Greece, Hungary, United Kingdom, Portugal, Ireland, Norway, Slovenia, Denmark, Sweden
Pearl Therapeutics, Inc.

Completed

Study to Assess the Efficacy and Safety of Three Doses of PT001 in Japanese Subjects With Moderate to Severe COPD

Chronic Obstructive Pulmonary Disease

Japan
Convalife (Shanghai) Co., Ltd.

Not yet recruiting

CVL237 Tablets in the Treatment of Advanced Solid Tumors With PTEN Deficiency

Advanced Solid Tumors

China
Novartis Pharmaceuticals

Withdrawn

Safety and Efficacy of NVA237 as an add-on to Fixed Dose Combination LABA/ICS (GLOW8)

Chronic Obstructive Pulmonary Disease
Pearl Therapeutics, Inc.

Completed

PK Study of PT003 and PT001 in Japanese Healthy Subjects

COPD

United States
Orion Corporation, Orion Pharma

Completed

Study to Compare Relative Bioavailability of 3 Indacaterol/Glycopyrronium Test Products and Reference Product (FORELLI)

Healthy Volunteers

Finland
Novartis Pharmaceuticals

Completed

A Study of the Efficacy and Safety of NVA237 in Patients With Moderate to Severe COPD

Chronic Obstructive Pulmonary Disease

Germany, Poland, Romania, Hungary, Sweden, Russian Federation, Bulgaria, Finland, Israel, Belgium
University of Saskatchewan

Completed

Effect of a LAMA and a uLABA on the Methacholine Dose-response Curve

Asthma

Canada
Inventiva Pharma

Completed

Phase 2b Study in NASH to Assess IVA337 (NATIVE)

Non-Alcoholic Steatohepatitis (NASH)

United States, Spain, United Kingdom, France, Belgium, Austria, Switzerland, Australia, Germany, Slovenia, Bulgaria, Canada, Czechia, Italy, Mauritius, Poland
Inventiva Pharma

Completed

Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis (FASST)

Scleroderma, Diffuse | Diffuse Cutaneous Systemic Sclerosis

United Kingdom, France, Spain, Switzerland, Italy, Slovenia, Netherlands, Germany, Bulgaria, Poland
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)

Neuromyelitis Optica (NMO) | NMO Spectrum Disorder (NMOSD)

United States, Korea, Republic of, Malaysia, Turkey, Bulgaria, Canada, Poland, Puerto Rico, Romania, Croatia, Georgia, Italy, Philippines, Taiwan, Ukraine
Inventiva Pharma

Recruiting

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) (NATiV3)

NASH - Nonalcoholic Steatohepatitis

United States, Argentina, Australia, Austria, Belgium, France, Germany, Israel, Portugal, Spain, United Kingdom, Canada, Italy, China, Brazil, Netherlands, Hungary, Bulgaria, Chile, Czechia, Mexico, Poland, Puerto Rico, South Africa, Uk...
Pearl Therapeutics, Inc.

Completed

Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD

Chronic Obstructive Pulmonary Disease

United States, Germany, United Kingdom, China, Taiwan, Korea, Republic of, Japan, Czechia, Hungary, Poland, Russian Federation
Pearl Therapeutics, Inc.

Completed

24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003 and Placebo MDI

COPD
Novartis Pharmaceuticals

Withdrawn

Study of Efficacy and Safety of NVA237 in Patients With Poorly Controlled Asthma

Asthma
Novartis

Completed

Safety and Tolerability of Multiple Inhaled NVA237 Doses in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease (COPD)

Germany, Denmark
Novartis Pharmaceuticals

Completed

Comparing the Pharmacokinetics, Safety and Tolerability of NVA237 in Renal Impairment

Renal Impairment

Russian Federation
Journey Medical Corporation

Completed

Comparator Study of the Effect of Glycopyrrolate and Glycopyrronium in Subjects With Axillary Hyperhidrosis

Hyperhidrosis

United States, Canada
Novartis Pharmaceuticals

Completed

Effect of Glycopyrronium on Morning Symptoms and Pulmonary Function in Patients With Moderate to Severe COPD

COPD

Germany, Spain, United Kingdom, Italy
Novartis Pharmaceuticals

Completed

Efficacy, Safety and Tolerability of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (GLOW7)

Chronic Obstructive Pulmonary Disease (COPD)

China, Philippines, Korea, Republic of, India
Novartis Pharmaceuticals

Completed

Efficacy, Tolerability and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

Australia, New Zealand
Novartis Pharmaceuticals

Completed

NVA237 BID Versus Placebo Twelve-week Efficacy Study

Chronic Obstructive Pulmonary Disease

United States
Novartis Pharmaceuticals

Completed

NVA237 Versus Placebo 12-week Efficacy Study

Chronic Obstructive Pulmonary Disease

United States
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study to Assess the Efficacy and Safety of HRG2005 Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

China
Novartis Pharmaceuticals

Completed

Efficacy of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD) (FAST)

Chronic Obstructive Pulmonary Disease

Germany
Novartis Pharmaceuticals

Completed

Comparison of Safety and Efficacy of the Combination Product QVA149A Against the Concurrent Administration of the Individual Components, QAB149 and NVA237, in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BEACON)

Chronic Obstructive Pulmonary Disease

Netherlands, Austria, Denmark, Norway, Sweden
Novartis Pharmaceuticals

Completed

Efficacy, Safety, and Tolerability of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD) (GLOW5)

Chronic Obstructive Pulmonary Disease

Germany, India, South Africa, Croatia, Estonia, Poland, Lithuania, Guatemala, Czech Republic, France, Philippines, Korea, Republic of, Taiwan, Canada, Latvia
Pearl Therapeutics, Inc.

Completed

24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003, Open-Label Spiriva® Respimat® as an Active Control, and Placebo

COPD
Novartis Pharmaceuticals

Completed

Swiss studY for the Treatment of COPD Patients With the Free combiNation of indacatERol and GlYcopyrroniumbromide. (SYNERGY)

Chronic Obstructive Pulmonary Disease: COPD

Switzerland
Sunovion Respiratory Development Inc.

Completed

Study to Determine the Amount of Glycopyrrolate Absorbed in the Lungs After Taking the Medicine With a eFlow Nebulizer and Seebri® Breezhaler® With and Without Activated Charcoal in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD). (GOLDEN7)

COPD

United Kingdom
Novartis Pharmaceuticals

Completed

A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.

Chronic Obstructive Pulmonary Disease (COPD)

United States, Poland, Romania, Canada, Philippines, Spain, Ukraine, Vietnam
Novartis

Completed

A Study to Investigate the Bronchodilatory Effect of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States, Germany
Novartis Pharmaceuticals

Completed

A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation

Chronic Obstructive Pulmonary Disease (COPD)

United States, Colombia, Egypt, Hungary, France, Guatemala, Panama, Slovakia, Slovenia
Novartis Pharmaceuticals

Completed

Effect of NVA237 on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease (COPD) (GLOW3)

Chronic Obstructive Pulmonary Disease

Germany, United Kingdom, Italy, United States, Romania
Novartis Pharmaceuticals

Completed

Long Term Safety Study of NVA237 vs QAB149 in COPD Patients

Chronic Obstructive Pulmonary Disease (COPD)

United States
GlaxoSmithKline

Completed

A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Argentina, Germany, Romania, Russian Federation, Chile, Sweden, Spain, Hungary, Czechia, Norway
Journey Medical Corporation

Completed

Study of Glycopyrronium in Axillary Hyperhydrosis

Hyperhidrosis

United States, Germany
Taipei Medical University Shuang Ho Hospital

Unknown

Utilizing Wearable Device to Observe the Clinical Response of COPD Patients Treated With Combined Bronchodilator and Home-based Pulmonary Rehabilitation Program

Chronic Obstructive Pulmonary Disease

Taiwan
Journey Medical Corporation

Completed

A Study of Glycopyrronium Cloth, 2.4% in Patients With Palmar Hyperhidrosis

Palmar Hyperhidrosis

United States
Eurofarma Laboratorios S.A.

Not yet recruiting

Study of Fluticasone/Formoterol/Glycopyrronium for the Treatment Chronic Obstructive Pulmonary Disease (TRIPLAR) (TRIPLAR)

Chronic Obstructive Pulmonary Disease

Brazil
University of Utah

Completed

Qbrexza Cloths for Hyperhidrosis of Amputation Sites

Hyperhidrosis | Amputation

United States
Journey Medical Corporation

Completed

Long-term Safety Study of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis

Hyperhidrosis

United States, Germany

Search clinical trials for: glycopyrronium (NVA237)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Qatar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations